VP-14637 ViroPharma

Curr Opin Investig Drugs. 2000 Dec;1(4):425-7.

Abstract

VP-14637 is the lead compound in a series of low molecular weight viral replication inhibitors which are under preclinical investigation by ViroPharma for the potential treatment of RSV infection [322651]. Phase I trials designed to evaluate the safety and pharmacokinetic prpfile of VR-14637 in healthy human volunteers have begun [385870]. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity [363716], [361097].

MeSH terms

  • Animals
  • Antiviral Agents / metabolism
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Antiviral Agents / toxicity
  • Clinical Trials as Topic
  • Drugs, Investigational
  • Humans
  • Hydrazones
  • Phenols / metabolism
  • Phenols / pharmacology
  • Phenols / therapeutic use*
  • Phenols / toxicity
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Respiratory Syncytial Virus Infections / virology
  • Respiratory Syncytial Virus, Human / drug effects
  • Structure-Activity Relationship
  • Tetrazoles / metabolism
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*
  • Tetrazoles / toxicity

Substances

  • Antiviral Agents
  • Drugs, Investigational
  • Hydrazones
  • Phenols
  • Tetrazoles
  • VP-14637